Truist Monetary Corp trimmed its stake in shares of Bio-Techne Co. (NASDAQ:TECH) by 7.4% within the third quarter, in accordance with the corporate in its most up-to-date Type 13F submitting with the Securities & Trade Fee. The fund owned 6,713 shares of the biotechnology firm’s inventory after promoting 538 shares throughout the interval. Truist Monetary Corp’s holdings in Bio-Techne have been price $3,253,000 as of its most up-to-date SEC submitting.
A number of different hedge funds and different institutional traders additionally lately made adjustments to their positions in TECH. Daiwa Securities Group Inc. lifted its stake in Bio-Techne by 56.0% within the third quarter. Daiwa Securities Group Inc. now owns 2,975 shares of the biotechnology firm’s inventory price $1,442,000 after buying an extra 1,068 shares within the final quarter. Advisor Group Holdings Inc. lifted its stake in Bio-Techne by 6.2% within the third quarter. Advisor Group Holdings Inc. now owns 9,103 shares of the biotechnology firm’s inventory price $4,414,000 after buying an extra 528 shares within the final quarter. Dai Ichi Life Insurance coverage Firm Ltd bought a brand new stake in Bio-Techne within the third quarter price about $2,281,000. Deutsche Financial institution AG lifted its stake in Bio-Techne by 49.8% within the third quarter. Deutsche Financial institution AG now owns 99,154 shares of the biotechnology firm’s inventory price $48,048,000 after buying an extra 32,958 shares within the final quarter. Lastly, Mitsubishi UFJ Kokusai Asset Administration Co. Ltd. lifted its stake in Bio-Techne by 89.5% within the third quarter. Mitsubishi UFJ Kokusai Asset Administration Co. Ltd. now owns 16,531 shares of the biotechnology firm’s inventory price $8,010,000 after buying an extra 7,806 shares within the final quarter. 92.57% of the inventory is owned by institutional traders and hedge funds.
A variety of analysis corporations have lately weighed in on TECH. Zacks Funding Analysis downgraded Bio-Techne from a “maintain” ranking to a “promote” ranking in a analysis notice on Wednesday, December eighth. Robert W. Baird raised their value goal on Bio-Techne from $522.00 to $548.00 and gave the inventory an “outperform” ranking in a analysis notice on Wednesday, November third. One analyst has rated the inventory with a promote ranking, one has issued a maintain ranking and 7 have assigned a purchase ranking to the corporate. Based mostly on information from MarketBeat.com, the inventory has a mean ranking of “Purchase” and a consensus value goal of $486.00.
In associated information, insider Kim Kelderman offered 500 shares of Bio-Techne inventory in a transaction on Friday, November nineteenth. The inventory was offered at a mean value of $505.38, for a complete transaction of $252,690.00. The sale was disclosed in a authorized submitting with the Securities & Trade Fee, which is out there by means of the SEC web site. Additionally, CFO James Hippel offered 662 shares of Bio-Techne inventory in a transaction on Friday, October twenty ninth. The inventory was offered at a mean value of $525.23, for a complete worth of $347,702.26. The disclosure for this sale may be discovered right here. Insiders offered a complete of 28,321 shares of firm inventory valued at $14,288,528 over the past three months. Insiders personal 4.10% of the corporate’s inventory.
Bio-Techne inventory opened at $397.68 on Friday. The corporate has a debt-to-equity ratio of 0.17, a present ratio of 4.06 and a fast ratio of three.18. The corporate has a market capitalization of $15.63 billion, a PE ratio of 91.84, a price-to-earnings-growth ratio of three.01 and a beta of 1.15. Bio-Techne Co. has a one yr low of $311.03 and a one yr excessive of $543.85. The enterprise has a 50 day easy transferring common of $476.24 and a 200 day easy transferring common of $484.26.
Bio-Techne (NASDAQ:TECH) final posted its earnings outcomes on Monday, November 1st. The biotechnology firm reported $1.83 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.72 by $0.11. Bio-Techne had a return on fairness of 15.86% and a web margin of 17.94%. The enterprise had income of $257.72 million throughout the quarter, in comparison with the consensus estimate of $254.37 million. Throughout the identical quarter final yr, the corporate earned $1.15 EPS. Equities analysts anticipate that Bio-Techne Co. will publish 6.84 earnings per share for the present fiscal yr.
The corporate additionally lately introduced a quarterly dividend, which was paid on Friday, November twenty sixth. Stockholders of report on Friday, November twelfth have been paid a $0.32 dividend. The ex-dividend date was Wednesday, November tenth. This represents a $1.28 annualized dividend and a dividend yield of 0.32%. Bio-Techne’s dividend payout ratio (DPR) is at the moment 29.56%.
Bio-Techne Corp. engages within the improvement, manufacture and sale of biotechnology reagents and devices for the analysis and medical diagnostic markets. It operates by means of the next segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences phase develops and manufactures purified proteins and reagent options most notably cytokines and development elements, antibodies, immunoassays, biologically energetic small molecule compounds, tissue tradition reagents and T-Cell activation applied sciences.
Featured Article: Asset Allocation and Your Retirement
Wish to see what different hedge funds are holding TECH? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Bio-Techne Co. (NASDAQ:TECH).
Need Extra Nice Investing Concepts?